- Home
- FEDU vs CGTX Comparison
FEDU vs CGTX Comparison
Compare FEDU & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- CGTX
- Stock Information
- Founded
- FEDU 2007
- CGTX 2007
- Country
- FEDU China
- CGTX United States
- Employees
- FEDU N/A
- CGTX N/A
- Industry
- FEDU
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- CGTX Health Care
- Exchange
- FEDU NYSE
- CGTX Nasdaq
- Market Cap
- FEDU 21.6M
- CGTX 20.5M
- IPO Year
- FEDU 2017
- CGTX 2021
- Fundamental
- Price
- FEDU $10.38
- CGTX $0.30
- Analyst Decision
- FEDU
- CGTX Strong Buy
- Analyst Count
- FEDU 0
- CGTX 5
- Target Price
- FEDU N/A
- CGTX $5.63
- AVG Volume (30 Days)
- FEDU 693.0
- CGTX 1.9M
- Earning Date
- FEDU 07-07-2025
- CGTX 08-07-2025
- Dividend Yield
- FEDU 22.17%
- CGTX N/A
- EPS Growth
- FEDU N/A
- CGTX N/A
- EPS
- FEDU 0.05
- CGTX N/A
- Revenue
- FEDU $34,475,202.00
- CGTX N/A
- Revenue This Year
- FEDU N/A
- CGTX N/A
- Revenue Next Year
- FEDU N/A
- CGTX N/A
- P/E Ratio
- FEDU $190.74
- CGTX N/A
- Revenue Growth
- FEDU 100.15
- CGTX N/A
- 52 Week Low
- FEDU $3.69
- CGTX $0.22
- 52 Week High
- FEDU $22.70
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- FEDU 70.57
- CGTX 48.87
- Support Level
- FEDU $9.49
- CGTX $0.25
- Resistance Level
- FEDU $10.90
- CGTX $0.33
- Average True Range (ATR)
- FEDU 0.19
- CGTX 0.03
- MACD
- FEDU 0.01
- CGTX 0.00
- Stochastic Oscillator
- FEDU 79.68
- CGTX 58.69
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.